Clinical significance of post‐progression survival in lung cancer
نویسندگان
چکیده
Progression-free survival (PFS) and overall survival (OS) are two common endpoints in cancer trials. OS is usually preferred, because it is reliable, precise, meaningful, and can easily be documented. However, subsequent lines of therapy might confound the effects of first-line treatment on OS. Whether PFS or OS is the more appropriate endpoint in clinical trials of metastatic cancer remains controversial. Previous reports on lung cancer have shown that an increase in PFS does not necessarily result in an increase in OS; however, post-progression survival (PPS) is strongly associated with OS after early-line treatment. The significance of PPS after first and second-line therapy at the individual level in patients with advanced lung cancer has also recently been reported. Findings of previous reports indicate that PPS is highly associated with OS after first and second-line chemotherapy in patients with advanced non-small cell lung cancer and small cell lung cancer, whereas PFS is only moderately associated with OS. Therefore, subsequent treatment after disease progression following early-line treatments may greatly influence OS. This review demonstrates that even in advanced lung cancer, PPS, rather than PFS, has become more strongly associated with OS over the years, potentially because of intensive post-study treatments. As a result of the increasing impact of PPS on OS, a PFS-related advantage does not necessarily indicate an OS-related advantage. Thus, the prolongation of PPS might limit the classical role of OS for assessing true efficacy derived from early-line chemotherapy in future clinical trials.
منابع مشابه
Survival and Prognostic Factors in Small Cell Lung Cancer Patients in Turkey
Background: Small cell lung cancer (SCLC) is a highly aggressive tumor. Objective: To evaluate the survival and time to progression of patients with SCLC admitted to a chest disease center in Istanbul, Turkey. Methods: Based on the reports of a pulmonary oncology clinic, data regarding performance status (PS), clinical stage of disease, treatment, time to progression and survival of 67 patients...
متن کاملThe Clinical and Prognostic Significance of Triple-Negative Status Invasive Breast Cancer in a Sample of Iraqi Women
Introduction: Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor, progesterone receptor, and HER2. This study aimed to evaluate the clinical outcomes and short-term prognosis of this type of cancer compared with other subtypes of breast cancer. Methods: A cross-sectional study was conducted on 108 women with invasive breast cancer. The patie...
متن کاملPrognostic value of various metabolic parameters on pre-treatment 18-F-FDG PET/CT in patients with stage I-III non-small cell lung cancer
Background: the aim of this study was to investigate the prognostic value of 18Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters in both overall survival and progression-free survival in Stage I-III non-small cell lung cancer (NSCLC). Materials and Methods: In this retrospective study, 267 patients who were diagnosed as Stage I-III non-smal...
متن کاملComparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
Aims: The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice. Methods: This single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage IIIB, IV) non-small cell lung cancer and Eastern Cooperative O...
متن کاملComparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
Aims: The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice. Methods: This single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage IIIB, IV) non-small cell lung cancer and Eastern Cooperative O...
متن کامل